10-QPeriod: Q3 FY2016

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q3 Ended Sep 30, 2016

Filed October 31, 2016For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. reported a net loss of $38.8 million for the third quarter of 2016, a significant improvement from a net loss of $95.1 million in the same period last year. This improvement was driven by a substantial increase in total revenues, which grew by 34% to $413.8 million, primarily fueled by strong growth in product revenues. ORKAMBI and KALYDECO were the key drivers, with ORKAMBI revenue increasing by 79% to $234.0 million and KALYDECO revenue growing by 6% to $175.6 million. Despite the revenue growth, operating costs and expenses also increased, by 14% to $432.5 million, largely due to higher research and development and cost of product revenues. The company continues to invest heavily in its pipeline, particularly in cystic fibrosis therapies. Looking ahead, Vertex anticipates continued revenue growth from its approved products and progress in its extensive clinical development programs, aiming to solidify its position in the CF market and explore new therapeutic areas.

Financial Highlights

49 data points
Beta

Revenue

$413.78M

87.1% Gross Margin

Net Income

-$38.84M

-9.4% Net Margin

EPS (Diluted)

$-0.16

Total Assets

$2.61B

Cash & Equivalents

$719.69M

Free Cash Flow

$51.77M

Financial Statements
Beta
Revenue$413.78M
Cost of Revenue$53.22M
Gross Profit$360.56M
R&D Expenses$272.37M
SG&A Expenses$106.06M
Operating Expenses$432.51M
Operating Income-$18.73M
Net Income-$38.84M
EPS (Basic)$-0.16
EPS (Diluted)$-0.16
Shares Outstanding (Basic)244.92M
Shares Outstanding (Diluted)244.92M

Key Highlights

  • 1Total revenues increased by 34% year-over-year to $413.8 million, driven by robust product sales.
  • 2Net loss attributable to Vertex narrowed significantly to $38.8 million from $95.1 million in the prior year's quarter.
  • 3ORKAMBI product revenues saw substantial growth, increasing by 79% to $234.0 million.
  • 4KALYDECO product revenues also increased, by 6% to $175.6 million.
  • 5Research and development expenses increased by 11% to $272.4 million, reflecting continued investment in pipeline development.
  • 6Sales, general and administrative expenses rose by 6% to $106.1 million, supporting commercial efforts.
  • 7The company ended the quarter with $1.13 billion in cash, cash equivalents, and marketable securities, indicating a strong liquidity position.

Frequently Asked Questions

Vertex's revenue growth was primarily driven by strong increases in product revenues from its key cystic fibrosis drugs, ORKAMBI and KALYDECO. ORKAMBI sales, in particular, showed significant growth due to its expanded label and market penetration.

Vertex reported a net loss of $38.8 million for the third quarter of 2016, which is a substantial improvement compared to the net loss of $95.1 million reported in the same quarter of 2015. This indicates improved profitability despite increased operating expenses.

Vertex maintains a strong liquidity position, ending the quarter with $1.13 billion in cash, cash equivalents, and marketable securities. This provides ample resources to fund ongoing operations, research, and development activities.

Vertex continues to invest heavily in its research and development pipeline, with a significant focus on cystic fibrosis therapies. This includes advancing next-generation CFTR corrector compounds and exploring novel targets such as ENaC inhibition. The company is also investing in early-stage programs in oncology, pain, and neurology.